SLB stock slips after RESMAN deal closes as Wall Street turns to earnings

SLB stock slips after RESMAN deal closes as Wall Street turns to earnings

New York, Jan 15, 2026, 15:08 EST — Regular session

Shares of SLB slipped 0.5% to $46.72 by 3:08 p.m. EST on Thursday, following news that the oilfield services firm finalized its acquisition of reservoir-monitoring expert RESMAN Energy Technology. The stock fluctuated between $46.11 and $46.89, with roughly 10.6 million shares changing hands. (SLB)

The RESMAN deal matters because it focuses on the work producers fund when they want to squeeze more oil and gas from existing wells. SLB has said RESMAN’s wireless reservoir surveillance and tracer technologies will speed up how quickly operators detect underground conditions and tweak production. (Energy Pedia)

Another area seeing strong demand is well clean-up, where SLB recently landed a new contract. Archer, partnering with SLB, secured an integrated plug-and-abandonment deal from Equinor for three wells on the Titan platform, Archer said, describing it as a project that “builds on our momentum.” Plug and abandonment, or P&A, involves sealing and decommissioning old wells. (Archer)

Archer outlined that the scope covers project management, well engineering, a compact workover rig, coiled tubing and wireline services, plus downhole P&A technologies. (MarketScreener)

Analysts are bracing for SLB’s upcoming earnings, though many warn the trade is crowded. Keith Mackey of RBC Capital bumped his price target on SLB from $43 to $51, maintaining an “Outperform” rating. Still, he flagged that matching the recent surge in optimism around oilfield services could prove “challenging” for both results and guidance. (TipRanks)

RBC boosted its price targets for several names in the group during its quarterly preview, including Halliburton and Baker Hughes. The target for Halliburton jumped to $36 from $31, while Baker Hughes saw its target rise to $57 from $54. Both stocks kept their outperform ratings, according to MT Newswires. (MarketScreener)

SLB is positioning RESMAN more as a production and recovery upgrade than a flashy headline deal. “This acquisition enhances SLB’s ability to deliver differentiated reservoir surveillance and production optimization solutions,” said Paul Sims, president of SLB’s Production Systems unit. (MarketScreener)

But bolt-on tech still demands smooth integration, and the benefits often don’t show up every quarter. If operators pull back on spending or push off projects, even basic monitoring and optimization can falter. The market usually penalizes anything that feels like a “good story, later numbers” scenario.

SLB’s next big event comes Jan. 23, with Q4 and full-year earnings dropping before the open and a conference call set for 9:30 a.m. ET. Investors want clear signals on activity levels and margins — plus an early check on whether RESMAN is making an impact in actual orders, not just in presentations. (SLB)

Stock Market Today

  • Madrigal Pharmaceuticals Shares Undervalued Despite Recent Declines
    February 4, 2026, 2:07 PM EST. Madrigal Pharmaceuticals (MDGL) has seen its stock drop 18.8% over 30 days but delivered a 49.4% return over the past year. The latest closing price was $482.45. Using discounted cash flow (DCF) analysis, which estimates future cash flow values in today's dollars, Madrigal appears 73.3% undervalued with an intrinsic value around $1,808 per share. The company reported a negative free cash flow of $164 million over the last year but is projected to generate about $1.8 billion in free cash flow by 2030. This suggests the market may be pricing the stock below its fundamental worth. Investors often use price-to-sales (P/S) ratios when earnings are volatile, providing another perspective on valuation in uncertain sectors like biotech.
Ondas stock slips ahead of Friday Investor Day as $1 billion deal hangs over shares
Previous Story

Ondas stock slips ahead of Friday Investor Day as $1 billion deal hangs over shares

Linde (LIN) stock barely budges in Wall Street rebound as Feb. 5 earnings date looms
Next Story

Linde (LIN) stock barely budges in Wall Street rebound as Feb. 5 earnings date looms

Go toTop